May 14, 2007 Toronto, Canada --NoAb BioDiscoveries announces the availability of DTEx™, a microarray-based
technology for profiling the effects of drugs on the gene expression of key proteins
involved in drug disposition. As “gatekeepers” for many drug compounds, drug
transporters along with metabolic enzymes play a critical role in determining the
pharmacodynamic and pharmacokinetic properties of administered drugs. Depending on
their levels in different cells, these proteins may alter intestinal uptake, renal excretion,
brain penetration, or uptake of drugs into target tissues. DTEx™ examines the drug’s
effects on the induction or suppression of these genes in biological systems. This
information will help scientists understand potential drug-drug interactions and to select
candidates for clinical development with greater efficacy and fewer side effects. NoAb
has filed patent applications for the DTEx™ technology.
